A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia

A H Simonsen; J McGuire; V N Podust; N-O Hagnelius; T K Nilsson; E Kapaki; D Vassilopoulos; G Waldemar

doi:10.1159/000110576

A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia

A H Simonsen, J McGuire, V N Podust, N-O Hagnelius, T K Nilsson, E Kapaki, D Vassilopoulos, G Waldemar

Afdeling for Hjerne- og Nervesygdomme

72 Citationer (Scopus)

Abstract

BACKGROUND: An early and accurate diagnosis of Alzheimer's disease (AD) is important in order to initiate symptomatic treatment with currently approved drugs and will be of even greater importance with the advent of disease-modifying compounds.

METHODS: Protein profiles of human cerebrospinal fluid samples from patients with AD (n = 85), frontotemporal dementia (n = 20), and healthy controls (n = 32) were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to verify previously discovered biomarkers.

RESULTS: We verified 15 protein biomarkers that were able to differentiate between AD and controls, and 7 of these 15 markers also differentiated AD from FTD.

CONCLUSION: A panel of cerebrospinal fluid protein markers was verified by a proteomics technology which may potentially improve the accuracy of the AD diagnosis.

Originalsprog	Engelsk
Tidsskrift	Dementia and Geriatric Cognitive Disorders
Vol/bind	24
Udgave nummer	6
Sider (fra-til)	434-40
Antal sider	7
ISSN	1420-8008
DOI	https://doi.org/10.1159/000110576
Status	Udgivet - 2007

Adgang til dokumentet

10.1159/000110576

Citationsformater

Simonsen, A. H., McGuire, J., Podust, V. N., Hagnelius, N.-O., Nilsson, T. K., Kapaki, E., Vassilopoulos, D., & Waldemar, G. (2007). A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dementia and Geriatric Cognitive Disorders, 24(6), 434-40. https://doi.org/10.1159/000110576

Simonsen, AH, McGuire, J, Podust, VN, Hagnelius, N-O, Nilsson, TK, Kapaki, E, Vassilopoulos, D & Waldemar, G 2007, 'A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia', Dementia and Geriatric Cognitive Disorders, bind 24, nr. 6, s. 434-40. https://doi.org/10.1159/000110576

@article{064975f7579c4661b13d5dbb69a33e4d,

title = "A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia",

abstract = "BACKGROUND: An early and accurate diagnosis of Alzheimer's disease (AD) is important in order to initiate symptomatic treatment with currently approved drugs and will be of even greater importance with the advent of disease-modifying compounds.METHODS: Protein profiles of human cerebrospinal fluid samples from patients with AD (n = 85), frontotemporal dementia (n = 20), and healthy controls (n = 32) were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to verify previously discovered biomarkers.RESULTS: We verified 15 protein biomarkers that were able to differentiate between AD and controls, and 7 of these 15 markers also differentiated AD from FTD.CONCLUSION: A panel of cerebrospinal fluid protein markers was verified by a proteomics technology which may potentially improve the accuracy of the AD diagnosis.",

keywords = "Aged, Aging/physiology, Alzheimer Disease/cerebrospinal fluid, Biomarkers, Chromogranin A/cerebrospinal fluid, Cystatin C, Cystatins/cerebrospinal fluid, Dementia/diagnosis, Diagnosis, Differential, Diagnostic and Statistical Manual of Mental Disorders, Female, Humans, Male, Middle Aged, ROC Curve, Ribonuclease, Pancreatic/cerebrospinal fluid",

author = "Simonsen, {A H} and J McGuire and Podust, {V N} and N-O Hagnelius and Nilsson, {T K} and E Kapaki and D Vassilopoulos and G Waldemar",

year = "2007",

doi = "10.1159/000110576",

language = "English",

volume = "24",

pages = "434--40",

journal = "Dementia and Geriatric Cognitive Disorders",

issn = "1420-8008",

publisher = "S. Karger AG",

number = "6",

}

TY - JOUR

T1 - A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia

AU - Simonsen, A H

AU - McGuire, J

AU - Podust, V N

AU - Hagnelius, N-O

AU - Nilsson, T K

AU - Kapaki, E

AU - Vassilopoulos, D

AU - Waldemar, G

PY - 2007

Y1 - 2007

N2 - BACKGROUND: An early and accurate diagnosis of Alzheimer's disease (AD) is important in order to initiate symptomatic treatment with currently approved drugs and will be of even greater importance with the advent of disease-modifying compounds.METHODS: Protein profiles of human cerebrospinal fluid samples from patients with AD (n = 85), frontotemporal dementia (n = 20), and healthy controls (n = 32) were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to verify previously discovered biomarkers.RESULTS: We verified 15 protein biomarkers that were able to differentiate between AD and controls, and 7 of these 15 markers also differentiated AD from FTD.CONCLUSION: A panel of cerebrospinal fluid protein markers was verified by a proteomics technology which may potentially improve the accuracy of the AD diagnosis.

AB - BACKGROUND: An early and accurate diagnosis of Alzheimer's disease (AD) is important in order to initiate symptomatic treatment with currently approved drugs and will be of even greater importance with the advent of disease-modifying compounds.METHODS: Protein profiles of human cerebrospinal fluid samples from patients with AD (n = 85), frontotemporal dementia (n = 20), and healthy controls (n = 32) were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to verify previously discovered biomarkers.RESULTS: We verified 15 protein biomarkers that were able to differentiate between AD and controls, and 7 of these 15 markers also differentiated AD from FTD.CONCLUSION: A panel of cerebrospinal fluid protein markers was verified by a proteomics technology which may potentially improve the accuracy of the AD diagnosis.

KW - Aged

KW - Aging/physiology

KW - Alzheimer Disease/cerebrospinal fluid

KW - Biomarkers

KW - Chromogranin A/cerebrospinal fluid

KW - Cystatin C

KW - Cystatins/cerebrospinal fluid

KW - Dementia/diagnosis

KW - Diagnosis, Differential

KW - Diagnostic and Statistical Manual of Mental Disorders

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - ROC Curve

KW - Ribonuclease, Pancreatic/cerebrospinal fluid

U2 - 10.1159/000110576

DO - 10.1159/000110576

M3 - Journal article

C2 - 17971664

SN - 1420-8008

VL - 24

SP - 434

EP - 440

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

IS - 6

ER -

A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater